drugset / Trial / NCT07714668
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
Timeline
- Start
- 2026-08-13
- Primary completion
- 2028-04-30
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Enlonstobart | Monoclonal antibody | 360 mg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | SYS6041 | Unknown | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |